220 related articles for article (PubMed ID: 20306246)
1. Genes predictive of outcome and novel molecular classification schemes in adult acute myeloid leukemia.
Verhaak RG; Valk PJ
Cancer Treat Res; 2010; 145():67-83. PubMed ID: 20306246
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling in acute myeloid leukemia.
Bullinger L; Valk PJ
J Clin Oncol; 2005 Sep; 23(26):6296-305. PubMed ID: 16155012
[TBL] [Abstract][Full Text] [Related]
3. Genetic classification of acute myeloid leukemia (AML).
Haferlach T; Schnittger S; Kern W; Hiddemann W; Schoch C
Ann Hematol; 2004; 83 Suppl 1():S97-100. PubMed ID: 15124693
[TBL] [Abstract][Full Text] [Related]
4. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
5. Gene expression with prognostic implications in cytogenetically normal acute myeloid leukemia.
Baldus CD; Bullinger L
Semin Oncol; 2008 Aug; 35(4):356-64. PubMed ID: 18692686
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling in acute myeloid leukaemia.
de Jonge HJ; Huls G; de Bont ES
Neth J Med; 2011 Apr; 69(4):167-76. PubMed ID: 21527803
[TBL] [Abstract][Full Text] [Related]
7. Has gene expression profiling improved diagnosis, classification, and outcome prediction in AML?
Willman CL
Best Pract Res Clin Haematol; 2008 Mar; 21(1):21-8. PubMed ID: 18342809
[TBL] [Abstract][Full Text] [Related]
8. Genomics in myeloid leukemias: an array of possibilities.
Bullinger L; Döner H; Pollack JR
Rev Clin Exp Hematol; 2005 Jun; 9(1):E2. PubMed ID: 16027104
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review.
Baldus CD; Mrózek K; Marcucci G; Bloomfield CD
Br J Haematol; 2007 Jun; 137(5):387-400. PubMed ID: 17488484
[TBL] [Abstract][Full Text] [Related]
10. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiling in acute myeloid leukaemia (AML).
Bacher U; Kohlmann A; Haferlach C; Haferlach T
Best Pract Res Clin Haematol; 2009 Jun; 22(2):169-80. PubMed ID: 19698926
[TBL] [Abstract][Full Text] [Related]
12. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.
Gröschel S; Lugthart S; Schlenk RF; Valk PJ; Eiwen K; Goudswaard C; van Putten WJ; Kayser S; Verdonck LF; Lübbert M; Ossenkoppele GJ; Germing U; Schmidt-Wolf I; Schlegelberger B; Krauter J; Ganser A; Döhner H; Löwenberg B; Döhner K; Delwel R
J Clin Oncol; 2010 Apr; 28(12):2101-7. PubMed ID: 20308656
[TBL] [Abstract][Full Text] [Related]
13. Current status of gene expression profiling in the diagnosis and management of acute leukaemia.
Bacher U; Kohlmann A; Haferlach T
Br J Haematol; 2009 Jun; 145(5):555-68. PubMed ID: 19344393
[TBL] [Abstract][Full Text] [Related]
14. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling.
Verhaak RG; Wouters BJ; Erpelinck CA; Abbas S; Beverloo HB; Lugthart S; Löwenberg B; Delwel R; Valk PJ
Haematologica; 2009 Jan; 94(1):131-4. PubMed ID: 18838472
[TBL] [Abstract][Full Text] [Related]
15. Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances.
Mrózek K; Döhner H; Bloomfield CD
Curr Opin Hematol; 2007 Mar; 14(2):106-14. PubMed ID: 17255787
[TBL] [Abstract][Full Text] [Related]
16. [The diagnosis of acute myeloid leukaemia enhanced by using DNA microarrays].
Löwenberg B; Delwel HR; Valk PJ
Ned Tijdschr Geneeskd; 2005 Mar; 149(12):623-5. PubMed ID: 15813428
[TBL] [Abstract][Full Text] [Related]
17. BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML).
Santamaría C; Chillón MC; García-Sanz R; Pérez C; Caballero MD; Mateos MV; Ramos F; de Coca AG; Alonso JM; Giraldo P; Bernal T; Queizán JA; Rodríguez JN; Puig N; Balanzategui A; Sarasquete ME; Alcoceba M; Díaz-Mediavilla J; San Miguel J; González M
Ann Hematol; 2010 May; 89(5):453-8. PubMed ID: 19943049
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of specific microRNA and their targets in acute myeloid leukemia.
Cammarata G; Augugliaro L; Salemi D; Agueli C; La Rosa M; Dagnino L; Civiletto G; Messana F; Marfia A; Bica MG; Cascio L; Floridia PM; Mineo AM; Russo M; Fabbiano F; Santoro A
Am J Hematol; 2010 May; 85(5):331-9. PubMed ID: 20425795
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization of acute myeloid leukemia and its impact on treatment.
Frankfurt O; Licht JD; Tallman MS
Curr Opin Oncol; 2007 Nov; 19(6):635-49. PubMed ID: 17906465
[TBL] [Abstract][Full Text] [Related]
20. Therapy of acute myeloid leukemia: towards a patient-oriented, risk-adapted approach.
Mandelli F; Petti MC; Lo Coco F
Haematologica; 1998 Nov; 83(11):1015-23. PubMed ID: 9864924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
